Icatibant for the treatment of hereditary angioedema

Annals of Pharmacotherapy

Volumn 47, Issue 1, 2013, Pages 49-55

  Cole, Sabrina W ^a   Lundquist, Lisa M ^b  

^a WINGATE UNIVERSITY   (United States)

^b MERCER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR; HISTAMINE; ICATIBANT; PLACEBO; PROSTACYCLIN; TRANEXAMIC ACID;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ARTICLE; BINDING AFFINITY; BLOOD VESSEL PERMEABILITY; DISTRIBUTION VOLUME; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; ENDOTHELIUM CELL; HEMATOMA; HISTAMINE RELEASE; HUMAN; HYPESTHESIA; INJECTION SITE BURNING; INJECTION SITE CONTUSION; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PARESTHESIA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; INJECTION SITE WARMTH; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SIDE EFFECT; SMOOTH MUSCLE CONTRACTION; STEADY STATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANGIOEDEMAS, HEREDITARY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; CLINICAL TRIALS, PHASE III AS TOPIC; COMPLEMENT C1 INHIBITOR PROTEIN; HUMANS; PEPTIDES; RECEPTORS, BRADYKININ; TRANEXAMIC ACID;

EID: 84872924903     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R423     Document Type: Article

References (23)

1. Riedl M. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus. Clin Ther 2012;34:623-630.
2. Reshef A, Leibovich I, Goren A. Hereditary angioedema: new hopes for an orphan disease. Isr Med Assoc J 2008;10:850-855.
3. Bork K. Recurrent angioedema and the threat of asphyxiaton. Dtsch Arztebl Int 2010;107:408-414.
4. Firszt R, Frank MM. An overview of novel therapies for acute hereditary angioedema. Am J Clin Dermatol 2010;11:383-388.
5. Christiansen SC, Zuraw BL. Hereditary angioedema: management of laryngeal attacks. Am J Rhinol Allergy 2011;25:379-382.
6. Product information. Cinryze (C1 esterase inhibitor [human]). Exton, PA: ViroPharm Biologics, Inc., December 2011.
7. Product information. Berinert (C1 esterase inhibitor [human]). Kankakee, IL: CSL Behring LLC, December 2011.
8. Product information. Kalbitor (ecallantide). Cambridge, MA: Dyax Corp., August 2011.
9. Product information. Firazyr (icatibant). Lexington, MA: Shire Orphan Therapies, Inc., August 2011.
10. Bouillet L. Icatibant in hereditary angioedema: news and challenges. Expert Rev Clin Immunol 2011;7:267-272.
11. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991;102:769-773.
12. Wirth K, Hock FJ, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991;102:774-777.
13. Swiss Pharmaceutical Society. index nominum: international drug directory. Medpharm Scientific Publishers. Electronic version, Thomson Reuters, Greenwood Village, CO. http://www.thomsonhc.com (accessed 2012 Aug 9).
14. Wagner F, Rosenkranz B, Knolle J. Absolute bioavailability of subcutaneously administered icatibant, a selective and potent bradykinin B2 receptor antagonist (abstract 1071). J Allergy Clin Immunol 2007;119:S274.
15. Longhurst HJ. Management of acute attacks of hereditary angioedema: potential role of icatibant. Vasc Health Risk Manag 2010;6:795-802.
16. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363:532-541.
17. Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011;107:529-537.
18. Maurer M, Church MK. Inflammatory skin responses induced by icatibant injection are mast cell mediated and attenuated by H1-antihistamines. Exp Dermatol 2011;21:154-160.
19. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-convertingenzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-1292.
20. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012;129:308-320.
21. Red book online. Thomson Reuters. http://www.thomsonhc.com/micromedex2/librarian/ND_T/evidencexpert/ND_PR/evidencexpert/CS/742D64/ND_AppProduct/evidencexpert/DUPLICATIONSHIELDSYNC/622144/ND_PG/evidencexpert/ND_B/evidencexpert/ND_P/evidencexpert/PFActionId/redbook.FindRedBook (accessed 2012 Jun 20).
22. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010;363:523-531.
23. Levy RL, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, doubleblind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104:523-529.